Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

423
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
423
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

Blood cancer journal·2026
Same author

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

American journal of hematology·2026
Same author

Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis.

American journal of hematology·2026
Same author

Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.

American journal of hematology·2026
Same author

New antifungals for the treatment of invasive mould disease.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

A Case Report of Tyrosine Kinase Inhibitor Interruption in a Patient with Multilineage Philadelphia-Positive Acute Lymphoblastic Leukemia.

Acta haematologica·2026

Related Experiment Video

Updated: Jan 2, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

495

The face of remission induction.

Shilpa Paul1, Caitlin R Rausch1, Elias J Jabbour2

  • 1Department of Clinical Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

British Journal of Haematology
|December 13, 2019
PubMed
Summary

Novel therapies offer a personalized approach to Acute Myeloid Leukaemia (AML) remission induction, moving beyond the traditional one-size-fits-all treatment model. This review explores the role of these new agents in AML treatment.

Keywords:
acute myeloid leukaemiainductionminimal residual diseasetargeted therapies

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.6K

Related Experiment Videos

Last Updated: Jan 2, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

495
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.6K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute Myeloid Leukaemia (AML) is a complex blood cancer with variable prognosis influenced by genetic mutations and patient factors.
  • Current remission induction therapy for AML has remained largely unchanged since 1973.
  • Advances in next-generation sequencing have deepened our understanding of AML pathogenesis.

Purpose of the Study:

  • To review the role of novel therapeutic agents in the remission induction phase of Acute Myeloid Leukaemia.
  • To highlight the shift towards patient-specific treatment strategies in AML.
  • To discuss targeted therapies approved since 2017 for specific AML subtypes or patient populations.

Main Methods:

  • Literature review of recent advancements in AML treatment.
  • Analysis of newly approved agents for Acute Myeloid Leukaemia.
  • Discussion of targeted therapy applications in remission induction.

Main Results:

  • Seven new targeted agents for AML have been approved since 2017.
  • These agents are designed for specific molecular subtypes or patient groups.
  • The development of targeted therapies enables a personalized approach to AML treatment.

Conclusions:

  • Novel therapies are transforming AML remission induction by enabling personalized treatment strategies.
  • The future of AML management involves tailoring treatments based on individual disease biology and patient characteristics.
  • Targeted agents represent a significant advancement over the historical 'one-size-fits-all' approach to AML therapy.